Hikal Concall:
To ensure stable availability, pricing of key raw materials we have embarked upon a strategic vendor development, de-risking the supply chain from China as well as backward integration to assure the appropriate raw material availability, which is on track.
1/n

Hikal Concall on rest of the year: We expect a sequential recovery and Q3 to Q4 will be better than Q2. We will end the year back on a strong note and Q4, we'll come back to pre-2022 levels.
2/n

Hikal Concall on CDMO: CDMO will start contributing to the business from first quarter of next year. So, for next year, you will see a big shift in our business on pharma side of CDMO. Crop is already primarily CDMO driven
3/n

Hikal concall on EBIT margins: The second question is when do you expect to see the business go back to September '21 type of level? I think we expect that to start happening from early part of next financial year.
4/n